Cannabinoid Compound Found to Reduce Asthma-Related Airway Inflammation in New Study
- The study found that JWH133, a synthetic CB2 receptor agonist, significantly reduced airway inflammation and hyperresponsiveness in a mouse model of allergic asthma.
- Experiments showed that JWH133 decreased inflammatory markers such as eosinophilic infiltration and Th2 cytokines (IL-4, IL-5, IL-13) and improved lung tissue health in ovalbumin-induced asthmatic mice.
- The effects of JWH133 were mainly mediated through CB2 receptor activation, as shown by partial reversal with the CB2 antagonist AM630, but involvement of other mechanisms like TRPV1 channels was also indicated.
- The research supports potential therapeutic roles for CB2-targeting cannabinoid compounds in managing asthma and airway inflammation, encouraging further studies despite being limited to animal models.
A new study published in Recent Advances in Inflammation & Allergy Drug Discovery found that JWH133, a synthetic compound designed to mimic the effects of natural CB2 receptor agonists such as those found in marijuana, reduced airway inflammation and hyperresponsiveness in a mouse model of allergic asthma.
The study was conducted by researchers from Ankara Yıldırım Beyazıt University and Al-Qalam University College. Researchers examined the effects of JWH133, a selective CB2 receptor agonist, in female BALB/c mice with ovalbumin-induced asthma.
Asthma is a chronic airway disease marked by inflammation, airway remodeling and increased sensitivity of the airways. CB2 receptors, which are part of the body’s endocannabinoid system, are increasingly being studied for their role in immune regulation. The study also examined whether TRPV1 channels may be involved in the compound’s effects.
Mice exposed to ovalbumin showed increased airway hyperresponsiveness, higher inflammatory cell counts in bronchoalveolar lavage fluid, elevated Th2 cytokines including IL-4, IL-5 and IL-13, and signs of lung inflammation. Treatment with JWH133 produced a dose-dependent reduction in airway hyperresponsiveness, eosinophilic infiltration and Th2 cytokine production, while also improving lung histology.
When researchers administered AM630, a CB2 antagonist, it partially reversed the effects of JWH133, suggesting CB2 activation played a central role. However, JWH133 retained some activity even when CB2 signaling was blocked, indicating other mechanisms may also be involved. Treatment involving the TRPV1 antagonist capsazepine also pointed to possible cannabinoid-TRP channel interactions.
Researchers concluded that JWH133 “markedly reduces airway hyperresponsiveness and inflammation” in ovalbumin-induced asthma, primarily through CB2 receptor activation but also through additional pathways.
The findings add to a growing body of research examining how cannabinoid-based compounds may influence inflammation, immune response and airway disease. While the study was conducted in mice and does not show that marijuana treats asthma, it supports further research into CB2-targeting therapies for asthma and related inflammatory conditions.